Becker's Healthcare November 22, 2021
Merck completed its acquisition of Acceleron Pharma for about $11.5 billion, the drugmaker said Nov. 22.
Merck announced its plan to acquire Acceleron in September, saying it would pay $180 per share in cash.
The acquisition expands Merck’s rare disease drug portfolio, as it allows the company to take over Acceleron’s lead drug candidate, sotatercept. Merck will also gain access...